About this journal
Aims and scope
Please note, from 2022 the Print ISSN is not in active use as this journal is no longer published in print.
Molecular & Cellular Oncology is an international journal publishing fundamental, translational and clinical research on all aspects of oncogenesis, tumor progression and therapeutic strategies.
Topics covered include:
- All solid and hematological cancers;
- Mechanistic insights into molecular pathways and cellular processes;
- Cell growth regulation, signal transduction, and apoptosis;
- Tumor microenvironment and immunosurveillance;
- Transcriptomics, proteomics, and metabolomics.
Molecular & Cellular Oncology publishes original research, reviews, short articles, commentaries, and author views.
*Please note that Molecular & Cellular Oncology converted to a full Open Access journal from Volume 9 (2022).
Publication office: Taylor & Francis, Inc., 530 Walnut Street, Suite 850, Philadelphia, PA 19106.
Journal metrics
Usage
- 175K annual downloads/views
Citation metrics
- 2.6 (2023) Impact Factor
- 1.6 (2023) 5 year IF
- 3.2 (2023) CiteScore (Scopus)
- 0.231 (2023) SNIP
- 0.471 (2023) SJR
Speed/acceptance
- 3 days avg. from submission to first decision
- 9% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editors-in-Chief
Lorenzo Galluzzi - Weill Cornell Medical College, New York, NY, US
Ilio Vitale - The University of Rome Tor Vergata, Rome, IT
Lorenzo Galluzzi - Weill Cornell Medical College, New York, NY, US
Guido Kroemer - University of Paris Descartes, Paris, FR
Scientific Advisory Board
Sandy Adjemian - VIB Center for Inflammation Research, Ghent, Belgium
David W. Andrews - University of Toronto, Toronto, ON, CA
Ralph DeBarardinis - Southwestern Medical Center, University of Texas, Dallas, TX, US
Niccolo Bartalucci, Center of Research and Innovation for Myeloproliferative Neoplasms (CRIMM), University of Florence, Italy
Jose Manuel Bravo-San Pedro, Universite de Paris, France
Eric Deutsch - Gustave-Roussy, France
Vishva Dixit - Genentech, Inc., South San Francisco, CA, US
Nicolas Dupont - INSERM, France
Manel Esteller - Bellvitge Institute for Biomedical Research, Barcelona, ES
Francesca Finotello - University of Innsbruck, Austria
Jose Manuel Fuentes - Universidad de Extremadura, Cáceres, ES
Dmitry I. Gabrilovich - The Wistar Institute, Philadelphia, PA, US
Abhishek Garg - KU Leuven, Belgium
Robyn Gartrell - Columbia University, USA
Francois Ghiringhelli - Centre Georges Francois Leclerc, France
Ana Patricia Da Silva Gomes - Moffitt Cancer Center, USA
Eyal Gottlieb - The Beatson Institute for Cancer Research, Glasgow, UK
Douglas R. Green - Memphis, TN, US
Congcong He - Northwestern University, USA
Jules A. Hoffmann - Institut de Biologie Moléculaire et Cellulaire, Strasbourg, FR
Richard A. Knight - University College London, London, UK
Guillermina Lozano - MD Anderson Cancer Center, University of Texas, Houston, TX, US
Alberto Mantovani - Humanitas Research Hospital, University of Milan, Rozzano, IT
Saverio Marchi - Marche Polytechnic University, Italy
Noboru Mizushima - The University of Tokyo, Tokyo, JP
Ute Moll - Stony Brook, NY, US
David Montrose - Stony Brook Medical Center, USA
Andrea Morandi - University of Florence, Italy
Gabriel Nunez - University of Michigan Medical School, Ann Arbor, MI, US
Moshe Oren - Weizmann Institute of Science, Rehovot, IL
Marcus E. Peter - Feinberg School of Medicine, Northwestern University, Chicago, IL, US
Federico Pietrocola - Karolinska Institute, Sweden
Paolo Ettore Porporato - University of Torino, Italy
Thomas Postler - Columbia University, USA
George Prendergast - The Lankenau Institute for Medical Research, Wynnewood, PA, US
Kodi Ravichandran - University of Virginia School of Medicine, Charlottesville, VA, US
Nicholas Restifo - Center for Cancer Research, National Cancer Institute - Chevy Chase, MD, US
Chiara Riganti - University of Torino, Italy
Nils-Petter Rudqvist - MD Anderson Cancer Center, University of Texas, USA
Maria Esperanza Rodriguez-Ruiz - Clinica Universidad de Navarra, Spain
Gregg L. Semenza - Johns Hopkins University School of Medicine, Baltimore, MD, US
Wen Shen - Weill Cornell Medical College, NY, USA
Mark Smyth - Herston, QLD, AU
Robbert Spaapen - Sanquin Research, University of Amsterdam, Netherlands
Clement Thomas - Luxembourg Institute of Health, Luxembourg
Sharon A. Tooze - London Research Institute, London, UK
Matthew G. Vander Heiden - Koch Institute, Massachusetts Institute of Technology, Cambridge, MA, US
Claire Vanpouille-Box - Weill Cornell Medical College, NY, USA
Peter K. Vogt - La Jolla, CA, US
Karen H. Vousden - Beatson Institute for Cancer Research, Glasgow, UK
Abstracting and indexing
- DOAJ
- National Library of Medicine
- PubMed Central (PMC) - Scopus
Open access
Molecular & Cellular Oncology is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
Continuous publication
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors